NCT01333540View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

June 30, 2012

Conditions
Opioid-induced Constipation (OIC)
Interventions
DRUG

TD-1211

Escalating doses

DRUG

Placebo

Placebo once daily

Trial Locations (1)

Unknown

Clinical Research Unit, Salt Lake City

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY